A case report of anti-tumor necrosis factor monoclonal antibody therapy for intestinal behçetʼs disease in an adolescent

2011 ◽  
pp. 1
Author(s):  
Itaru Iwama ◽  
Seiichi Kagimoto
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Necrosis Factor

scholarly journals Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

2017 ◽  
Vol 9 (2) ◽  
Author(s):  
Pablo Santa María ◽  
Fernando Valenzuela ◽  
Claudia Morales ◽  
Raul De la Fuente ◽  
Roberto Cullen
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Growth Factor ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Keratinocyte Growth Factor ◽  
Review Of The Literature ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor

We report the case of a 56-year old male with severe plaque psoriasis that was successfully treated with ixekizumab, a new anti interleukin (IL)-17 monoclonal antibody. During the first months of treatment he developed a lentiginous eruption in the sites of rapidly resolving plaques. Biopsy and immunohistochemistry reports showed elements of both lentigo and post-inflammatory hyper pigmentation. These findings, which have been increasingly described in anti-tumor necrosis factor alpha (TNFα) and anti IL-12/IL-23 therapy, may be explained by the down regulating effect of TNFα and IL-17 on pigmentation genes, which is very rapidly suppressed by ixekizumab, resulting in hyper pigmentation, and by the alteration of mesenchymal-epidermal interaction via keratinocyte growth factor during the inflammatory period, which results in the development of histopathological elements of lentigo.

Sign in / Sign up

Export Citation Format

Share Document